COSCIENS Biopharma Inc (CSCI)

[livendi]

so macrilens 2 phase 3 trials in usa for cancer cachexia and tbi are worthless huh,do u have any idea what macrilens sales will be if macrilen is approved for these 2 indications,it would be gigantic and pedi approval is for an unmet need,again not a small thing,no way to test kids for ghd,if u dont have patience this stock isnt for u,just hold,much much better days coming,god bless all